These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 34003511)
1. Pathogenic ACVR1 Ramachandran A; Mehić M; Wasim L; Malinova D; Gori I; Blaszczyk BK; Carvalho DM; Shore EM; Jones C; Hyvönen M; Tolar P; Hill CS EMBO J; 2021 Jul; 40(14):e106317. PubMed ID: 34003511 [TBL] [Abstract][Full Text] [Related]
2. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling. Barruet E; Morales BM; Lwin W; White MP; Theodoris CV; Kim H; Urrutia A; Wong SA; Srivastava D; Hsiao EC Stem Cell Res Ther; 2016 Aug; 7(1):115. PubMed ID: 27530160 [TBL] [Abstract][Full Text] [Related]
3. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933 [TBL] [Abstract][Full Text] [Related]
4. The Fibrodysplasia Ossificans Progressiva (FOP) mutation p.R206H in ACVR1 confers an altered ligand response. Hildebrand L; Stange K; Deichsel A; Gossen M; Seemann P Cell Signal; 2017 Jan; 29():23-30. PubMed ID: 27713089 [TBL] [Abstract][Full Text] [Related]
5. Reduced GS Domain Serine/Threonine Requirements of Fibrodysplasia Ossificans Progressiva Mutant Type I BMP Receptor ACVR1 in the Zebrafish. Allen RS; Jones WD; Hale M; Warder BN; Shore EM; Mullins MC J Bone Miner Res; 2023 Sep; 38(9):1364-1385. PubMed ID: 37329499 [TBL] [Abstract][Full Text] [Related]
6. Activin A forms a non-signaling complex with ACVR1 and type II Activin/BMP receptors via its finger 2 tip loop. Aykul S; Corpina RA; Goebel EJ; Cunanan CJ; Dimitriou A; Kim HJ; Zhang Q; Rafique A; Leidich R; Wang X; McClain J; Jimenez J; Nannuru KC; Rothman NJ; Lees-Shepard JB; Martinez-Hackert E; Murphy AJ; Thompson TB; Economides AN; Idone V Elife; 2020 Jun; 9():. PubMed ID: 32515349 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification. Yamamoto M; Stoessel SJ; Yamamoto S; Goldhamer DJ J Bone Miner Res; 2022 Nov; 37(11):2077-2093. PubMed ID: 35637634 [TBL] [Abstract][Full Text] [Related]
8. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva. Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737 [TBL] [Abstract][Full Text] [Related]
9. Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. Song GA; Kim HJ; Woo KM; Baek JH; Kim GS; Choi JY; Ryoo HM J Biol Chem; 2010 Jul; 285(29):22542-53. PubMed ID: 20463014 [TBL] [Abstract][Full Text] [Related]
10. AAV-Mediated Targeting of the Activin A-ACVR1 Yang YS; Lin C; Ma H; Xie J; Kaplan FS; Gao G; Shim JH Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759764 [TBL] [Abstract][Full Text] [Related]
11. Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1 Wentworth KL; Lalonde RL; Groppe JC; Brewer N; Moody T; Hansberry S; Taylor KE; Shore EM; Kaplan FS; Pignolo RJ; Yelick PC; Hsiao EC J Bone Miner Res; 2022 Nov; 37(11):2058-2076. PubMed ID: 36153796 [TBL] [Abstract][Full Text] [Related]
12. ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant. Haupt J; Deichsel A; Stange K; Ast C; Bocciardi R; Ravazzolo R; Di Rocco M; Ferrari P; Landi A; Kaplan FS; Shore EM; Reissner C; Seemann P Hum Mol Genet; 2014 Oct; 23(20):5364-77. PubMed ID: 24852373 [TBL] [Abstract][Full Text] [Related]
13. Allele-Selective LNA Gapmers for the Treatment of Fibrodysplasia Ossificans Progressiva Knock Down the Pathogenic ACVR1 Maruyama R; Nguyen Q; Roshmi RR; Touznik A; Yokota T Nucleic Acid Ther; 2022 Jun; 32(3):185-193. PubMed ID: 35085461 [TBL] [Abstract][Full Text] [Related]
14. Fibrodysplasia ossificans progressiva mutant ACVR1 signals by multiple modalities in the developing zebrafish. Allen RS; Tajer B; Shore EM; Mullins MC Elife; 2020 Sep; 9():. PubMed ID: 32897189 [TBL] [Abstract][Full Text] [Related]
15. Variable signaling activity by FOP ACVR1 mutations. Haupt J; Xu M; Shore EM Bone; 2018 Apr; 109():232-240. PubMed ID: 29097342 [TBL] [Abstract][Full Text] [Related]
16. The Activation of the Fibrodysplasia Ossificans Progressiva-Inducing ALK2-R206H Mutant Depends on the Distinct Homo-Oligomerization Patterns of ACVR2B and ACVR2A. Szilágyi SS; Burdzinski W; Jatzlau J; Ehrlich M; Knaus P; Henis YI Cells; 2024 Jan; 13(3):. PubMed ID: 38334613 [TBL] [Abstract][Full Text] [Related]
17. The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. Shen Q; Little SC; Xu M; Haupt J; Ast C; Katagiri T; Mundlos S; Seemann P; Kaplan FS; Mullins MC; Shore EM J Clin Invest; 2009 Nov; 119(11):3462-72. PubMed ID: 19855136 [TBL] [Abstract][Full Text] [Related]
19. Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases. Han HJ; Jain P; Resnick AC Bone; 2018 Apr; 109():91-100. PubMed ID: 28780023 [TBL] [Abstract][Full Text] [Related]
20. Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling. Xie C; Jiang W; Lacroix JJ; Luo Y; Hao J Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]